Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 16/20 | 0.57 |
| ▸ | DRD4 | P21917 | 7/20 | 0.57 |
| ▸ | DRD3 | P35462 | 7/20 | 0.57 |
| ▸ | DRD2 | P14416 | 6/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.57 |
| ▸ | HTR2B | P41595 | 2/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | SCN1A | P35498 | 2/20 | 0.57 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.57 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.57 |
| ▸ | HRH2 | P25021 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12216179 | 0.89 | KMT2A (0.54) | OPRM1DRD4DRD3DRD2KMT2A | |
| SCHEMBL12265221 | 0.86 | OPRM1 (0.58) | OPRM1DRD4DRD3DRD2KMT2A | |
| SCHEMBL12216076 | 0.86 | OPRM1 (0.56) | OPRM1DRD4DRD3DRD2KMT2A | |
| SCHEMBL12216162 | 0.81 | OPRM1 (0.54) | OPRM1DRD4DRD3DRD2KMT2A | |
| SCHEMBL12265229 | 0.81 | OPRM1 (0.54) | OPRM1DRD4DRD3DRD2KMT2A | |
| SCHEMBL2527593 | 0.81 | OPRM1 (0.53) | OPRM1DRD4DRD3DRD2KMT2A | |
| SCHEMBL12216070 | 0.81 | OPRM1 (0.53) | OPRM1DRD4DRD3DRD2KMT2A | |
| SCHEMBL13785133 | 0.80 | OPRM1 (0.58) | OPRM1DRD4DRD3DRD2KMT2A | |
| SCHEMBL10263502 | 0.79 | OPRM1 (0.53) | OPRM1DRD4DRD3DRD2KMT2A | |
| SCHEMBL13435360 | 0.78 | KCNA3 (0.59) | OPRM1KMT2ARAB9ANPSR1TET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039636-B2 | Methods for making 4-tetrazolyl-4-phenylpiperidine compounds | PURDUE PHARMA L.P. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039636-B2 | Methods for making 4-tetrazolyl-4-phenylpiperidine compounds | PURDUE PHARMA L.P. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039636-B2 | Methods for making 4-tetrazolyl-4-phenylpiperidine compounds | PURDUE PHARMA L.P. (US) | 2011-10-18 | — | — | US | disclosed |
| US-7687518-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687518-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090240056-A1 | METHODS FOR MAKING 4-TETRAZOLYL-4-PHENYLPIPERIDINE COMPOUNDS | EURO-CELTIQUE S.A. (LU) | 2009-09-24 | — | — | US | disclosed |
| US-20090240056-A1 | METHODS FOR MAKING 4-TETRAZOLYL-4-PHENYLPIPERIDINE COMPOUNDS | EURO-CELTIQUE S.A. (LU) | 2009-09-24 | — | — | US | disclosed |
| US-20090240056-A1 | METHODS FOR MAKING 4-TETRAZOLYL-4-PHENYLPIPERIDINE COMPOUNDS | EURO-CELTIQUE S.A. (LU) | 2009-09-24 | — | — | US | disclosed |
| US-7557219-B2 | Methods for making 4-tetrazolyl-4-phenylpiperidine compounds | PURDUE PHARMA L.P. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557219-B2 | Methods for making 4-tetrazolyl-4-phenylpiperidine compounds | PURDUE PHARMA L.P. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557219-B2 | Methods for making 4-tetrazolyl-4-phenylpiperidine compounds | PURDUE PHARMA L.P. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7202259-B2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2007-04-10 | — | — | US | disclosed |
| US-7202259-B2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2007-04-10 | — | — | US | disclosed |
| EP-1562932-B1 | 4-TETRAZOLYL-4-PHENYLPIPERIDINE DERIVATIVES FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2007-04-04 | — | — | EP | disclosed |
| US-20070072909-A1 | deblocking, deprotecting; debenzylation; for preventing pain, diarrhea | EURO-CELTIQUE S.A. | 2007-03-29 | — | — | US | disclosed |
| US-20070072909-A1 | deblocking, deprotecting; debenzylation; for preventing pain, diarrhea | EURO-CELTIQUE S.A. | 2007-03-29 | — | — | US | disclosed |
| US-20070072909-A1 | deblocking, deprotecting; debenzylation; for preventing pain, diarrhea | EURO-CELTIQUE S.A. | 2007-03-29 | — | — | US | disclosed |
| EP-1709029-A2 | METHODS FOR MAKING 4-TETRAZOLYL-4-PHENYLPIPERIDINE COMPOUNDS | EURO-CELTIQUE S.A. (LU) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005075455-A2 | METHODS FOR MAKING 4-TETRAZOLYL-4-PHENYLPIPERIDINE COMPOUNDS | EURO-CELTIQUE S.A. (LU) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072909-A1 | deblocking, deprotecting; debenzylation; for preventing pain, diarrhea | OPRL1, DECR1, PKD1 | OPRM1 250/4885DRD4 28/4885DRD3 7/4885 |
| US-20090240056-A1 | METHODS FOR MAKING 4-TETRAZOLYL-4-PHENYLPIPERIDINE COMPOUNDS | NAT1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, AHR | OPRM1 211/4885DRD4 43/4885DRD3 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.